3,4-dihydroxyphenylacetic acid has been researched along with Nerve Degeneration in 60 studies
3,4-Dihydroxyphenylacetic Acid: A deaminated metabolite of LEVODOPA.
(3,4-dihydroxyphenyl)acetic acid : A dihydroxyphenylacetic acid having the two hydroxy substituents located at the 3- and 4-positions. It is a metabolite of dopamine.
dihydroxyphenylacetic acid : A dihydroxy monocarboxylic acid consisting of phenylacetic acid having two phenolic hydroxy substituents.
Nerve Degeneration: Loss of functional activity and trophic degeneration of nerve axons and their terminal arborizations following the destruction of their cells of origin or interruption of their continuity with these cells. The pathology is characteristic of neurodegenerative diseases. Often the process of nerve degeneration is studied in research on neuroanatomical localization and correlation of the neurophysiology of neural pathways.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Current research on Parkinson's disease (PD) pathogenesis requires relevant animal models that mimic the gradual and progressive development of neuronal dysfunction and degeneration that characterizes the disease." | 1.42 | Progressive nigrostriatal terminal dysfunction and degeneration in the engrailed1 heterozygous mouse model of Parkinson's disease. ( Beauvais, G; Brundin, P; Escobar Galvis, ML; Feinstein, TN; Fuchs, J; Ghosh, A; Joshi, RL; Lipton, JW; Lundblad, M; Medicetty, S; Nordströma, U; Prochiantz, A; Pulikkaparambil Sasidharan, BC; Roholt, A; Steiner, JA, 2015) |
| "3% of the administered dose was taken up by the brain and was slowly eliminated, with a half-life of approximately 3 weeks." | 1.39 | Pharmacokinetic, neurochemical, stereological and neuropathological studies on the potential effects of paraquat in the substantia nigra pars compacta and striatum of male C57BL/6J mice. ( Beck, M; Botham, PA; Breckenridge, CB; Butt, M; Cook, AR; Mathews, JM; Minnema, D; Smith, LL; Sturgess, NC; Tisdel, MO; Travis, KZ; Wolf, JC; Zadory, D, 2013) |
| "In a well-established mouse model of Menkes disease, mottled-brindled (mo-br), we tested whether systemic administration of L-threo-dihydroxyphenylserine (L-DOPS), a drug used successfully to treat autosomal recessive norepinephrine deficiency, would improve brain neurochemical abnormalities and neuropathology." | 1.39 | L-threo-dihydroxyphenylserine corrects neurochemical abnormalities in a Menkes disease mouse model. ( Brinster, LR; Donsante, A; Goldstein, DS; Kaler, SG; Sullivan, P, 2013) |
| "elegans results in dopaminergic neuron degeneration, the effects of alpha-synuclein on dopamine homeostasis and its contribution to dopaminergic neuron degeneration in C." | 1.36 | Alpha-synuclein disrupted dopamine homeostasis leads to dopaminergic neuron degeneration in Caenorhabditis elegans. ( Cao, P; Feng, Z; Huang, Y; Moise, AR; Palczewski, K; Pehek, EA; Yuan, Y, 2010) |
| " Long recovery periods after MPP(+) exposure are required to distinguish between reversible or irreversible toxic and/or trophic effects." | 1.33 | Characterization of organotypic ventral mesencephalic cultures from embryonic mice and protection against MPP toxicity by GDNF. ( Gramsbergen, JB; Jakobsen, B; Møller Dall, A; Rosenblad, C; Zimmer, J, 2005) |
| " Therefore, the aim of the present study was to examine whether the long-term administration of a commonly used herbicide, paraquat, which has already been found to induce a slowly progressing degeneration of the nigrostriatal neurons, influences mesocortical dopaminergic neurons in rats." | 1.33 | Degeneration of dopaminergic mesocortical neurons and activation of compensatory processes induced by a long-term paraquat administration in rats: implications for Parkinson's disease. ( Biedka, I; Bortel, A; Dabrowska, J; Kuter, K; Nowak, P; Ossowska, K; Rommelspacher, H; Schulze, G; Smiałowska, M; Wardas, J; Wierońska, J; Zieba, B, 2006) |
| " Estrogen altered the toxic effects of the second invasion of MA as indicated by a significant decrease in striatal dopamine (DA) and 3,4-dihydroxyphenylacetic acid (DOPAC) concentrations." | 1.33 | Effect of estrogen upon methamphetamine-induced neurotoxicity within the impaired nigrostriatal dopaminergic system. ( Dluzen, DE; Liu, B, 2006) |
| "Behaviour was evaluated by catalepsy tests and activity box." | 1.32 | Potentiation of parkinsonian symptoms by depletion of locus coeruleus noradrenaline in 6-hydroxydopamine-induced partial degeneration of substantia nigra in rats. ( Schmidt, WJ; Srinivasan, J, 2003) |
| "Kainic acid (KA) was employed to induce neuronal lesions in the more dorsal striatum, the caudate-putamen (CP)." | 1.31 | Lesion of caudate-putamen interneurons with kainic acid alters dopamine and serotonin metabolism in the olfactory tubercle of the rat. ( Cubeddu, LX; Guevara, BH; Hoffmann, IS; Torrico, F, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (3.33) | 18.7374 |
| 1990's | 18 (30.00) | 18.2507 |
| 2000's | 29 (48.33) | 29.6817 |
| 2010's | 11 (18.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ehara, A | 1 |
| Nakadate, K | 1 |
| Sugimoto, H | 1 |
| Yoshimoto, K | 1 |
| Ueda, S | 1 |
| Breckenridge, CB | 1 |
| Sturgess, NC | 1 |
| Butt, M | 1 |
| Wolf, JC | 1 |
| Zadory, D | 1 |
| Beck, M | 1 |
| Mathews, JM | 1 |
| Tisdel, MO | 1 |
| Minnema, D | 1 |
| Travis, KZ | 1 |
| Cook, AR | 1 |
| Botham, PA | 1 |
| Smith, LL | 1 |
| Nordströma, U | 1 |
| Beauvais, G | 1 |
| Ghosh, A | 1 |
| Pulikkaparambil Sasidharan, BC | 1 |
| Lundblad, M | 1 |
| Fuchs, J | 1 |
| Joshi, RL | 1 |
| Lipton, JW | 1 |
| Roholt, A | 1 |
| Medicetty, S | 1 |
| Feinstein, TN | 1 |
| Steiner, JA | 1 |
| Escobar Galvis, ML | 1 |
| Prochiantz, A | 1 |
| Brundin, P | 1 |
| Saal, KA | 1 |
| Koch, JC | 1 |
| Tatenhorst, L | 1 |
| Szegő, EM | 1 |
| Ribas, VT | 1 |
| Michel, U | 1 |
| Bähr, M | 1 |
| Tönges, L | 1 |
| Lingor, P | 1 |
| Sharma, N | 1 |
| Nehru, B | 1 |
| Cheng, B | 1 |
| Yang, X | 1 |
| An, L | 1 |
| Gao, B | 1 |
| Liu, X | 1 |
| Liu, S | 1 |
| Cao, P | 1 |
| Yuan, Y | 1 |
| Pehek, EA | 2 |
| Moise, AR | 1 |
| Huang, Y | 1 |
| Palczewski, K | 1 |
| Feng, Z | 1 |
| Marcellino, D | 1 |
| Suárez-Boomgaard, D | 1 |
| Sánchez-Reina, MD | 1 |
| Aguirre, JA | 1 |
| Yoshitake, T | 1 |
| Yoshitake, S | 1 |
| Hagman, B | 1 |
| Kehr, J | 1 |
| Agnati, LF | 2 |
| Fuxe, K | 2 |
| Rivera, A | 1 |
| di Matteo, V | 1 |
| Pierucci, M | 1 |
| Di Giovanni, G | 1 |
| Dragani, LK | 1 |
| Murzilli, S | 1 |
| Poggi, A | 1 |
| Esposito, E | 1 |
| Shchepinov, MS | 1 |
| Chou, VP | 1 |
| Pollock, E | 1 |
| Langston, JW | 2 |
| Cantor, CR | 1 |
| Molinari, RJ | 1 |
| Manning-Boğ, AB | 2 |
| van Bregt, DR | 1 |
| Thomas, TC | 1 |
| Hinzman, JM | 1 |
| Cao, T | 1 |
| Liu, M | 1 |
| Bing, G | 2 |
| Gerhardt, GA | 2 |
| Pauly, JR | 1 |
| Lifshitz, J | 1 |
| Donsante, A | 1 |
| Sullivan, P | 1 |
| Goldstein, DS | 1 |
| Brinster, LR | 1 |
| Kaler, SG | 1 |
| Fitzmaurice, AG | 1 |
| Rhodes, SL | 1 |
| Lulla, A | 1 |
| Murphy, NP | 1 |
| Lam, HA | 1 |
| O'Donnell, KC | 1 |
| Barnhill, L | 1 |
| Casida, JE | 1 |
| Cockburn, M | 1 |
| Sagasti, A | 1 |
| Stahl, MC | 1 |
| Maidment, NT | 1 |
| Ritz, B | 1 |
| Bronstein, JM | 1 |
| McCormack, AL | 1 |
| Thiruchelvam, M | 1 |
| Thiffault, C | 1 |
| Cory-Slechta, DA | 1 |
| Di Monte, DA | 1 |
| Ricaurte, GA | 1 |
| Yuan, J | 1 |
| Hatzidimitriou, G | 1 |
| Cord, BJ | 1 |
| McCann, UD | 1 |
| Guevara, BH | 1 |
| Torrico, F | 1 |
| Hoffmann, IS | 1 |
| Cubeddu, LX | 1 |
| Srinivasan, J | 1 |
| Schmidt, WJ | 1 |
| Klivenyi, P | 1 |
| Calingasan, NY | 1 |
| Starkov, A | 1 |
| Stavrovskaya, IG | 1 |
| Kristal, BS | 1 |
| Yang, L | 1 |
| Wieringa, B | 1 |
| Beal, MF | 1 |
| Zaman, V | 1 |
| Nelson, ME | 1 |
| Rohrer, B | 1 |
| Götz, ME | 1 |
| Malz, CR | 1 |
| Dirr, A | 1 |
| Blum, D | 1 |
| Gsell, W | 1 |
| Schmidt, S | 1 |
| Burger, R | 1 |
| Pohli, S | 1 |
| Riederer, P | 2 |
| Jakobsen, B | 1 |
| Gramsbergen, JB | 1 |
| Møller Dall, A | 1 |
| Rosenblad, C | 1 |
| Zimmer, J | 1 |
| Li, X | 1 |
| Matsumoto, K | 1 |
| Murakami, Y | 1 |
| Tezuka, Y | 1 |
| Wu, Y | 1 |
| Kadota, S | 1 |
| Theodore, S | 1 |
| Cass, WA | 2 |
| Maragos, WF | 1 |
| Ossowska, K | 1 |
| Smiałowska, M | 1 |
| Kuter, K | 1 |
| Wierońska, J | 1 |
| Zieba, B | 1 |
| Wardas, J | 1 |
| Nowak, P | 1 |
| Dabrowska, J | 1 |
| Bortel, A | 1 |
| Biedka, I | 1 |
| Schulze, G | 1 |
| Rommelspacher, H | 1 |
| Liu, B | 2 |
| Dluzen, DE | 3 |
| Mazzulli, JR | 1 |
| Mishizen, AJ | 1 |
| Giasson, BI | 1 |
| Lynch, DR | 1 |
| Thomas, SA | 1 |
| Nakashima, A | 1 |
| Nagatsu, T | 2 |
| Ota, A | 1 |
| Ischiropoulos, H | 1 |
| Sawada, H | 1 |
| Hishida, R | 1 |
| Hirata, Y | 1 |
| Ono, K | 1 |
| Suzuki, H | 1 |
| Muramatsu, S | 1 |
| Nakano, I | 1 |
| Sawada, M | 1 |
| Rojo, AI | 1 |
| Cavada, C | 1 |
| de Sagarra, MR | 1 |
| Cuadrado, A | 1 |
| Rajeswari, A | 1 |
| Sabesan, M | 1 |
| Kadoguchi, N | 1 |
| Kimoto, H | 1 |
| Yano, R | 1 |
| Kato, H | 1 |
| Araki, T | 1 |
| Wuerthele, SM | 1 |
| Moore, KE | 1 |
| Lisoprawski, A | 1 |
| Herve, D | 1 |
| Blanc, G | 1 |
| Glowinski, J | 1 |
| Tassin, JP | 1 |
| Pu, C | 1 |
| Fisher, JE | 1 |
| Cappon, GD | 1 |
| Vorhees, CV | 1 |
| Oishi, T | 1 |
| Hasegawa, E | 1 |
| Murai, Y | 1 |
| Przedborski, S | 1 |
| Jackson-Lewis, V | 1 |
| Yokoyama, R | 1 |
| Shibata, T | 1 |
| Dawson, VL | 1 |
| Dawson, TM | 1 |
| Wesemann, W | 1 |
| Solbach, M | 1 |
| Nafe, R | 1 |
| Grote, C | 1 |
| Sontag, KH | 1 |
| Jellinger, K | 1 |
| Mennel, HD | 1 |
| Clement, HW | 1 |
| Tatton, WG | 1 |
| Wadia, JS | 1 |
| Ju, WY | 1 |
| Chalmers-Redman, RM | 1 |
| Tatton, NA | 1 |
| Lan, J | 1 |
| Jiang, DH | 1 |
| Wei, Q | 1 |
| Jurma, OP | 1 |
| Andersen, JK | 1 |
| Takeda, A | 1 |
| Sawashita, J | 1 |
| Takefuta, S | 1 |
| Okada, S | 1 |
| Teicher, MH | 1 |
| Andersen, SL | 1 |
| Campbell, A | 1 |
| Gelbard, HA | 1 |
| Baldessarini, RJ | 1 |
| Lindner, MD | 1 |
| Cain, CK | 1 |
| Plone, MA | 1 |
| Frydel, BR | 1 |
| Blaney, TJ | 1 |
| Emerich, DF | 1 |
| Hoane, MR | 1 |
| Youdim, MB | 3 |
| Grünblatt, E | 1 |
| Mandel, S | 1 |
| Moy, LY | 1 |
| Zeevalk, GD | 1 |
| Sonsalla, PK | 1 |
| Kim, H | 1 |
| Jhoo, W | 1 |
| Shin, E | 1 |
| Disshon, KA | 1 |
| Liang, SL | 1 |
| Pan, JT | 1 |
| Bezard, E | 1 |
| Jaber, M | 1 |
| Gonon, F | 1 |
| Boireau, A | 1 |
| Bloch, B | 1 |
| Gross, CE | 1 |
| Rabinovic, AD | 1 |
| Lewis, DA | 1 |
| Hastings, TG | 1 |
| Halladay, AK | 1 |
| Yue, Y | 1 |
| Michna, L | 1 |
| Widmer, DA | 1 |
| Wagner, GC | 1 |
| Zhou, R | 1 |
| Fox, CM | 1 |
| Gash, DM | 1 |
| Smoot, MK | 1 |
| Li, SW | 1 |
| Lin, TS | 1 |
| Minteer, S | 1 |
| Burke, WJ | 1 |
| Janson, AM | 2 |
| Rosén, L | 1 |
| Finnman, UB | 1 |
| Tanganelli, S | 1 |
| Morari, M | 1 |
| Goldstein, M | 1 |
| Crock, R | 1 |
| Yamamoto, BK | 1 |
| Sengstock, GJ | 1 |
| Olanow, CW | 1 |
| Dunn, AJ | 1 |
| Arendash, GW | 1 |
| Ben-Shachar, D | 2 |
| Pinhassi, B | 1 |
| Pasinetti, GM | 1 |
| Kohama, S | 1 |
| Reinhard, JF | 1 |
| Cheng, HW | 1 |
| McNeill, TH | 1 |
| Finch, CE | 1 |
| Meana, JJ | 1 |
| Goiny, M | 1 |
| Herrera-Marschitz, M | 1 |
| Eshel, G | 1 |
| Finberg, JP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Starving for Energy - A Pilot Study to Test Ketone Derived Energy in Eating Disorders[NCT05507008] | 40 participants (Anticipated) | Interventional | 2022-10-13 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for 3,4-dihydroxyphenylacetic acid and Nerve Degeneration
| Article | Year |
|---|---|
(-)-Deprenyl reduces neuronal apoptosis and facilitates neuronal outgrowth by altering protein synthesis without inhibiting monoamine oxidase.
Topics: 3,4-Dihydroxyphenylacetic Acid; Alzheimer Disease; Animals; Apoptosis; Cells, Cultured; Gene Express | 1996 |
Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Disease | 1997 |
58 other studies available for 3,4-dihydroxyphenylacetic acid and Nerve Degeneration
| Article | Year |
|---|---|
Role of neuronal nitric oxide synthase in slowly progressive dopaminergic neurodegeneration in the Zitter rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Base Sequence; Caudate Nucleus; Dopamine; Dopaminergic Neur | 2018 |
Pharmacokinetic, neurochemical, stereological and neuropathological studies on the potential effects of paraquat in the substantia nigra pars compacta and striatum of male C57BL/6J mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Astrocytes; B | 2013 |
Progressive nigrostriatal terminal dysfunction and degeneration in the engrailed1 heterozygous mouse model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Autophagy; Corpus Striatum; Disease Models, Animal; Disease | 2015 |
AAV.shRNA-mediated downregulation of ROCK2 attenuates degeneration of dopaminergic neurons in toxin-induced models of Parkinson's disease in vitro and in vivo.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Dependovirus; Disease Models, Animal; Do | 2015 |
Apocyanin, a Microglial NADPH Oxidase Inhibitor Prevents Dopaminergic Neuronal Degeneration in Lipopolysaccharide-Induced Parkinson's Disease Model.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetophenones; Animals; Cytokines; Disease Models, Animal; Dopaminer | 2016 |
Ketogenic diet protects dopaminergic neurons against 6-OHDA neurotoxicity via up-regulating glutathione in a rat model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Brain; Brain Chemistry; Chromatography, | 2009 |
Alpha-synuclein disrupted dopamine homeostasis leads to dopaminergic neuron degeneration in Caenorhabditis elegans.
Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Animals; Animals, Genetically Modified; Caenorhabdi | 2010 |
On the role of P2X(7) receptors in dopamine nerve cell degeneration in a rat model of Parkinson's disease: studies with the P2X(7) receptor antagonist A-438079.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Analysis of Variance; Animals; Brain; Cell Count; | 2010 |
Intake of tomato-enriched diet protects from 6-hydroxydopamine-induced degeneration of rat nigral dopaminergic neurons.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Carotenoids; Disease Models, Animal; Dopamine; Functional L | 2009 |
Isotopic reinforcement of essential polyunsaturated fatty acids diminishes nigrostriatal degeneration in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; alpha-Linolenic Acid; | 2011 |
Substantia nigra vulnerability after a single moderate diffuse brain injury in the rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Atrophy; Brain Injuries; Calcium-Binding Proteins; Carrier | 2012 |
L-threo-dihydroxyphenylserine corrects neurochemical abnormalities in a Menkes disease mouse model.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenosine Triphosphatases; Animals; Antiparkinson Agents; Blood-Brai | 2013 |
Aldehyde dehydrogenase inhibition as a pathogenic mechanism in Parkinson disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aldehyde Dehydrogenase; Animals; Benomyl; Dopaminergic Neurons; Flow | 2013 |
Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat.
Topics: 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Biomarkers; Dopamine; Environm | 2002 |
RETRACTED: Severe dopaminergic neurotoxicity in primates after a common recreational dose regimen of MDMA ("ecstasy").
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Autoradiography; Axons; Brain; Carrier Proteins; Corpus Str | 2002 |
Lesion of caudate-putamen interneurons with kainic acid alters dopamine and serotonin metabolism in the olfactory tubercle of the rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Cell Death; Dopamine; Dose-Response Relat | 2002 |
Potentiation of parkinsonian symptoms by depletion of locus coeruleus noradrenaline in 6-hydroxydopamine-induced partial degeneration of substantia nigra in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Behavior, Animal; Benzylamines; Cataleps | 2003 |
Neuroprotective mechanisms of creatine occur in the absence of mitochondrial creatine kinase.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenosine Monophosphate; Animals; Brain; Brain Chemistry; Chromatogr | 2004 |
Neurodegenerative alterations in the nigrostriatal system of trkB hypomorphic mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain-Derived Neurotrophic Factor; Chromatography, High Pre | 2004 |
Brain aging phenomena in migrating sockeye salmon Oncorhynchus nerka nerka.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aging; Animal Migration; Animals; Antioxidants; Apoptosis; Brain; Ca | 2005 |
Characterization of organotypic ventral mesencephalic cultures from embryonic mice and protection against MPP toxicity by GDNF.
Topics: 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Cell Differentiation; Cell Pro | 2005 |
Neuroprotective effects of Polygonum multiflorum on nigrostriatal dopaminergic degeneration induced by paraquat and maneb in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Chromatography, High Pressure Liquid; | 2005 |
Methamphetamine and human immunodeficiency virus protein Tat synergize to destroy dopaminergic terminals in the rat striatum.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Biomarkers; Blotting, Western; Central Nervous System Stimu | 2006 |
Degeneration of dopaminergic mesocortical neurons and activation of compensatory processes induced by a long-term paraquat administration in rats: implications for Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Cerebral Cortex; Chromatography, High Pre | 2006 |
Effect of estrogen upon methamphetamine-induced neurotoxicity within the impaired nigrostriatal dopaminergic system.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Uptake Inhibitors; Animals; Corpus Striatum; Disease Mode | 2006 |
Effects of estrogen and related agents upon methamphetamine-induced neurotoxicity within an impaired nigrostriatal dopaminergic system of ovariectomized mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Androgens; Animals; Dopamine; Dopamine Agents; Dose-Response Relatio | 2006 |
Cytosolic catechols inhibit alpha-synuclein aggregation and facilitate the formation of intracellular soluble oligomeric intermediates.
Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Amino Acid Substitution; Animals; Catechols; Cell D | 2006 |
Activated microglia affect the nigro-striatal dopamine neurons differently in neonatal and aged mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Aging; Animals; Animal | 2007 |
Chronic inhalation of rotenone or paraquat does not induce Parkinson's disease symptoms in mice or rats.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Administration, Inhala | 2007 |
Inhibition of monoamine oxidase-B by the polyphenolic compound, curcumin and its metabolite tetrahydrocurcumin, in a model of Parkinson's disease induced by MPTP neurodegeneration in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Curcumin; Dis | 2008 |
Failure of acute administration with proteasome inhibitor to provide a model of Parkinson's disease in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 2008 |
Effect of systemic and intrastriatal injections of haloperidol on striatal dopamine and DOPAC concentrations in rats pretreated by section of nigrostriatal fibres.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dopamine; Feedback; Glutamate Decarboxylas | 1980 |
Selective activation of the mesocortico-frontal dopaminergic neurons induced by lesion of the habenula in the rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Choline O-Acetyltransferase; Dominance, Cerebral; Dopamine; | 1980 |
The effects of amfonelic acid, a dopamine uptake inhibitor, on methamphetamine-induced dopaminergic terminal degeneration and astrocytic response in rat striatum.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Astrocytes; Chromatography, High Pressure Liquid; Dopamine; | 1994 |
Sulfhydryl drugs reduce neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striat | 1993 |
Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cerebellum; Corpus Striatum; Dopamine; Dopamine Agents; Enz | 1996 |
Effect of lazaroid U-74389G on iron-induced reduction of striatal dopamine metabolism.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antioxidants; Corpus Striatum; Dopamine; Injections; Iron; | 1995 |
Increased expression of monoamine oxidase-B results in enhanced neurite degeneration in methamphetamine-treated PC12 cells.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cell Survival; Dopamine; Dopamine Agents; Hydrogen Peroxide | 1997 |
Distribution of zinc in the substantia nigra of rats treated with 6-hydroxydopamine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Autoradiography; Blood-Brain Barrier; Ch | 1998 |
Progressive accumbens degeneration after neonatal striatal 6-hydroxydopamine in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Animals, Newborn; Caudate Nucleus; Chromatography, High Pre | 1998 |
Incomplete nigrostriatal dopaminergic cell loss and partial reductions in striatal dopamine produce akinesia, rigidity, tremor and cognitive deficits in middle-aged rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Age Factors; Animals; Brain Mapping; Corpus Striatum; Dementia; Dopa | 1999 |
The pivotal role of iron in NF-kappa B activation and nigrostriatal dopaminergic neurodegeneration. Prospects for neuroprotection in Parkinson's disease with iron chelators.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Ani | 1999 |
Role for dopamine in malonate-induced damage in vivo in striatum and in vitro in mesencephalic cultures.
Topics: 2H-Benzo(a)quinolizin-2-ol, 2-Ethyl-1,3,4,6,7,11b-hexahydro-3-isobutyl-9,10-dimethoxy-; 3,4-Dihydrox | 2000 |
Selenium deficiency potentiates methamphetamine-induced nigral neuronal loss; comparison with MPTP model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Antioxidants; | 2000 |
Estrogen reduces acute striatal dopamine responses in vivo to the neurotoxin MPP+ in female, but not male rats.
Topics: 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dopamine; Est | 2000 |
An endogenous serotonergic rhythm acting on 5-HT(2A) receptors may be involved in the diurnal changes in tuberoinfundibular dopaminergic neuronal activity and prolactin secretion in female rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; 5,7-Dihydroxytryptamine; 8-Hydroxy-2-(di-n-propylamino)tetralin; Amp | 2000 |
Adaptive changes in the nigrostriatal pathway in response to increased 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration in the mouse.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Carrier Proteins; Cell Count; Corpus Striatum; Disease Mode | 2000 |
Role of oxidative changes in the degeneration of dopamine terminals after injection of neurotoxic levels of dopamine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cysteine; Dopamine; Down-Regulation; Extracellular Space; G | 2000 |
Regulation of EphB1 expression by dopamine signaling.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Animals, Newborn; Cerebral Cortex; Cocaine; Cocaine-Related | 2000 |
Neuroprotective effects of GDNF against 6-OHDA in young and aged rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aging; Animals; Cell Survival; Dopamine; Glial Cell Line-Derived Neu | 2001 |
3,4-Dihydroxyphenylacetaldehyde and hydrogen peroxide generate a hydroxyl radical: possible role in Parkinson's disease pathogenesis.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aldehydes; Brain; Catechols; Humans; Hydrogen Peroxide; Hydrox | 2001 |
Evidence for a protective action of the vigilance promoting drug modafinil on the MPTP-induced degeneration of the nigrostriatal dopamine neurons in the black mouse: an immunocytochemical and biochemical analysis.
Topics: 3,4-Dihydroxyphenylacetic Acid; Anesthesia, General; Animals; Benzhydryl Compounds; Central Nervous | 1992 |
Selective subregional dopamine depletions in the rat caudate-putamen following nigrostriatal lesions.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Caudate Nucleus; Corpus Striatum; Dopamine; Homovanillic Ac | 1992 |
Iron induces degeneration of nigrostriatal neurons.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Homovanillic Acid; Iron; Male; Nerve Degen | 1992 |
Prevention of neuroleptic-induced dopamine D2 receptor supersensitivity by chronic iron salt treatment.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antipsychotic Agents; Apomorphine; Brain Chemistry; Chlorpr | 1991 |
Striatal responses to decortication. I. Dopaminergic and astrocytic activities.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Astrocytes; Biomarkers; Blotting, Western; Cerebral Cortex; | 1991 |
Chronic nicotine treatment counteracts the decrease in extracellular neostriatal dopamine induced by a unilateral transection at the mesodiencephalic junction in rats: a microdialysis study.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcholine; Animals; Corpus Striatum; Denervation; Depression, Ch | 1991 |
The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Deferoxamine; Dopamine; Homovanillic Acid; Hydroxydopamines | 1991 |